Precipio Diagnostics Prices $2.7M Direct Offering

Nov 03, 2017

NEW YORK (GenomeWeb) – Precipio Diagnostics announced today that it has priced a $2.7 million registered direct offering of equity units.

According to the company, it will offer for sale 2,748 units, each consisting of one share of Series C preferred stock convertible at $1.40 per share, and warrants to purchase up to roughly 1.9 million shares of common stock at an exercise price of $1.63 per share.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

Featured White Papers

ABBOTT Informatics STARLIMS Solution Helps Precision Diagnostics Achieve Compliance and Retain Customers

Discovering Neuronal Cell Types

Immuno-Oncology: 3 Strategies for Applying Humanized Models

A Guide to Selecting Your Next Immuno-Oncology Model

Jun

26

Featured Webinar

The Landscape of Alternative Polyadenylation in the Lung Cancer Transcriptome

This webinar outlines a study that sought to characterize the landscape of alternative polyadenylation (APA) in the lung cancer transcriptome in order to gain insight into the role of APA in cancer progression.

Jul

10

Featured Webinar

Case Study: Genetic Testing Lab Sees 25-Fold Scaleup with New Informatics System

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Jul

19

Featured Webinar

Advances in NGS for Ultra-High Sensitivity Applications in Translational and Clinical Research

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.

Jul

25

Featured Webinar

Antibiotic Gene Surveillance: What You Don’t See Can Hurt You!

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms.

Main menu